All authors
Claude Skills by dromlakhani
github.com/dromlakhani875 skills0 installs1,377 views
- Endo Paget Bisphosphonate Pre Joint ReplacementThis skill suggests administering a bisphosphonate before elective total joint replacement to reduce intraoperative hemorrhaging and postoperative loosening of the prosthesis in patients with severe osteoarthritis adjacent to Paget's disease bone. Trigger phrases include preoperative planning for joint replacement in a patient with Paget's disease affecting the adjacent bone.Votes: 0GitHub stars: 12
- Endo Paget Bisphosphonate Pre Osteotomy BowingRecommends administering a potent bisphosphonate prior to elective osteotomy for severe lower‑extremity bowing in Paget’s disease that causes impaired ambulation or severe joint pain. Triggered when planning surgical correction of a lower‑extremity deformity in a patient diagnosed with Paget’s disease.Votes: 0GitHub stars: 12
- Endo Paget Bisphosphonate Treatment IndicationRecommends treatment with a bisphosphonate for most patients with active Paget's disease who are at risk of future complications. Triggers include active Paget's disease with risk of fracture, deformity, or neurologic symptoms.Votes: 0GitHub stars: 12
- Endo Paget Bone Marker Liver DysfunctionRecommends measuring a specific bone formation or resorption marker in patients with Paget's disease who have abnormal liver or biliary tract function to assess treatment response or disease evolution. Triggered when liver function tests (e.g., ALT, AST, ALP, bilirubin) are abnormal in a patient with known Paget's disease.Votes: 0GitHub stars: 12
- Endo Paget Early Response AssessmentThis skill outlines using short-term changes in bone resorption markers (e.g., serum CTx or urine NTx) before and shortly after bisphosphonate therapy to predict an adequate therapeutic response. It is triggered when there is urgency to control severe symptoms or when Paget’s disease is highly active, prompting rapid efficacy assessment.Votes: 0GitHub stars: 12
- Endo Paget Hearing Loss PreventionSuggests treatment with a potent bisphosphonate to prevent worsening of a hearing deficit in patients with Paget's disease involving the temporal bone. Triggers include detected or suspected hearing loss thought to be related to Paget's disease.Votes: 0GitHub stars: 12
- Endo Paget Initial Biochemical EvaluationRecommends obtaining serum total alkaline phosphatase or a more specific bone formation marker for initial biochemical evaluation after radiological confirmation of Paget’s disease. Triggered after imaging establishes diagnosis to set baseline bone turnover.Votes: 0GitHub stars: 12
- Endo Paget Lsc Biomarker InterpretationUses the least significant change (LSC) derived from analytical and biological variation to determine whether two sequential bone turnover marker measurements reflect a true biological difference. Triggers include when monitoring biomarker trends to assess treatment response or disease progression in Paget’s disease.Votes: 0GitHub stars: 12
- Endo Paget Monostotic Activity AssessmentAssesses biochemical activity in untreated monostotic Paget's disease by measuring P1NP or BSAP and CTx or NTx when scintigraphy shows disease activity despite normal total alkaline phosphatase. Triggered when evaluating disease activity in patients with suspected or confirmed monostotic (single‑site) Paget's disease.Votes: 0GitHub stars: 12
- Endo Paget Plain Radiographs SuspectedRecommends obtaining plain radiographs of the suspicious regions of the skeleton in patients with suspected Paget's disease. Clinical triggers include unexplained bone pain, elevated alkaline phosphatase, or clinical suspicion based on presentation.Votes: 0GitHub stars: 12
- Endo Paget Radionuclide Bone Scan ExtentThis skill suggests performing a radionuclide bone scan to determine the extent of Paget's disease and identify asymptomatic sites after diagnosis. It is triggered when Paget's disease is diagnosed and a baseline extent assessment is needed.Votes: 0GitHub stars: 12
- Endo Paget Remission Target TurnoverSuggests reducing bone turnover below the midpoint of the reference range for the chosen monitoring bone turnover marker to maximize the duration of remission. Triggered when aiming to sustain long-term remission after treatment and the marker exceeds the midpoint.Votes: 0GitHub stars: 12
- Endo Paget Repeat Xray Osteolytic LesionsThis skill outlines when to obtain a repeat radiograph approximately one year after radiological diagnosis of osteolytic lesions in Paget's disease to assess lesion improvement or worsening. Consider repeat imaging if biochemical markers of bone turnover remain elevated or bone pain persists despite therapy.Votes: 0GitHub stars: 12
- Endo Paget Retreatment Interval BisphosphonateThis skill determines the appropriate retreatment interval for bisphosphonate therapy in Paget's disease based on drug-specific remission duration. It is triggered when planning long-term management after an initial bisphosphonate course, considering retreatment for zoledronate (seldom within 5 years), alendronate (maybe 2–6 years), or risedronate (maybe 1–5 years).Votes: 0GitHub stars: 12
- Endo Paget Zoledronate Choice DoseSuggests a single 5‑mg intravenous dose of zoledronate as the treatment of choice in patients with active Paget’s disease who have no contraindication to IV zoledronate. Triggered when initiating pharmacologic therapy for Paget’s disease and confirming absence of renal impairment or other contraindications.Votes: 0GitHub stars: 12
- Gc Overreplacement Fracture RiskRecommends vertebral fracture assessment (baseline spinal x-ray or DXA) to identify unsuspected vertebral fractures in men over-replaced with glucocorticoids and at fracture risk. Use when evaluating a male hypopituitarism patient on glucocorticoids with fracture risk factors such as age >50, prior fracture, or low BMD.Votes: 0GitHub stars: 12
- Endo Ace Arb Ccb HtnRecommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?'Votes: 0GitHub stars: 12
- Endo Antidiabetic WeightlossRecommends adding a glucose‑lowering agent that promotes weight loss (GLP‑1 agonist or SGLT‑2 inhibitor) to metformin for overweight or obese patients with type 2 diabetes. Triggered when a clinician asks which drug to add to metformin for weight loss in an obese T2DM patient or whether to prefer a GLP‑1 agonist over insulin for its weight‑loss benefit.Votes: 0GitHub stars: 12
- Endo Avoid Offlabel WeightlossAdvises against using medications approved for other indications solely for weight loss, except in research contexts or by providers with weight‑management expertise managing well‑informed patients. Common triggers include questions such as 'Is it appropriate to prescribe topiramate off‑label for weight loss in this patient?' or 'Should I avoid off‑label bupropion for obesity treatment outside a research setting?'.Votes: 0GitHub stars: 12
- Endo Avoid Sympathomimetic CvdRecommends using non‑sympathomimetic agents (lorcaserin, orlistat) for pharmacological weight loss in patients with cardiovascular disease. Triggers include clinician questions such as “What weight‑loss medication is safest for this patient with coronary artery disease?” or “Should I avoid phentermine in a patient with prior stroke seeking obesity treatment?”.Votes: 0GitHub stars: 12
- Endo Avoid Sympathomimetic HtnRecommends against using sympathomimetic agents (phentermine, diethylpropion) in patients with uncontrolled hypertension or a history of heart disease. Triggers include clinician questions such as “Is it safe to prescribe phentermine for this patient with uncontrolled hypertension?” or “Should I avoid sympathomimetics in a patient with prior MI seeking weight‑loss medication?”.Votes: 0GitHub stars: 12
- Endo Bariatric EligibilityDetermines if a patient is a candidate for bariatric surgery using BMI thresholds: BMI ≥35 kg/m2 with comorbidity or BMI ≥40 kg/m2 regardless of comorbidities. Triggers include when a clinician asks, 'Is this patient eligible for bariatric surgery given their BMI and comorbidities?' or 'Should I refer a patient with BMI 38 and sleep apnea for surgical evaluation?'.Votes: 0GitHub stars: 12
- Endo Comorbidities EvaluationThe skill evaluates all patients with acromegaly for hypertension, diabetes mellitus, cardiovascular disease, osteoarthritis, and sleep apnea at initial assessment. It is triggered by a new diagnosis of acromegaly or when a patient presents for baseline endocrine workup.Votes: 0GitHub stars: 12
- Endo Comorbidities Longitudinal MonitoringThis skill recommends longitudinal monitoring and rigorous management of identified comorbidities—such as hypertension, diabetes mellitus, cardiovascular disease, osteoarthritis, and sleep apnea—in patients with acromegaly. Apply throughout follow‑up when comorbidities are present to mitigate morbidity and mortality risk.Votes: 0GitHub stars: 12
- Endo Doc OfflabelWe need to output a SKILL.md file with the specified format.Votes: 0GitHub stars: 12
- Endo Dose EscalationGuides dose escalation for obesity pharmacotherapy based on efficacy and tolerability while staying within approved upper dose limits. Triggers include clinician questions like "How should I titrate naltrexone/bupropion if the starting dose is tolerated?" or "What is the maximum liraglutide dose I can use?"Votes: 0GitHub stars: 12
- Endo Efficacy 5pctThis skill guides clinicians to assess whether a patient has achieved ≥5% weight loss at 3 months while on a weight‑loss medication and to determine continuation versus discontinuation based on efficacy and safety. It is triggered when a clinician asks, 'Has this patient lost enough weight at 3 months to continue lorcaserin?' or 'Should I stop phentermine/topiramate because the patient lost only 3% of body weight?'.Votes: 0GitHub stars: 12
- Endo Followup AssessmentAdvises assessing efficacy and safety at least monthly for the first 3 months, then at least every 3 months for all patients prescribed weight‑loss medications. Triggers include clinician questions such as “How often should I check progress after starting orlistat?” or “What is the follow‑up schedule for a patient on liraglutide?”.Votes: 0GitHub stars: 12
- Endo Less Sedating AntihistamineRecommends selecting antihistamines with reduced central nervous system activity (less sedation) to minimize weight‑gain risk. Triggers include clinician questions such as “Which antihistamine is least likely to cause weight gain for this patient with allergies?” or “Should I prefer a non‑sedating antihistamine over diphenhydramine for this obese patient?"Votes: 0GitHub stars: 12
- Endo Lifestyle Mod Bmi25Recommends that diet, exercise, and behavioral modification be included in all obesity management approaches for patients with a BMI of 25 kg/m2 or higher. Triggered when clinicians ask, 'What foundational non-pharmacologic therapy should I start for this overweight patient?' or 'Should I initiate lifestyle changes for a patient with BMI 26?'.Votes: 0GitHub stars: 12
- Endo Monitor Weight Waist ArtRecommends regular monitoring of weight and waist circumference in patients receiving antiretroviral therapy due to unavoidable weight gain, redistribution, and associated cardiovascular risk. Triggered when a clinician asks, 'How often should I check weight and waist in this patient on ART?' or 'What parameters should I track to detect ART‑related weight changes?'Votes: 0GitHub stars: 12
- Endo Pharmaco EligibilityDetermines if a patient is a candidate for pharmacotherapy based on BMI thresholds: BMI ≥27 kg/m2 with at least one obesity-related comorbidity or BMI ≥30 kg/m2 regardless of comorbidities. Triggered when a clinician asks, “Does this patient qualify for weight‑loss medication based on BMI and comorbidities?” or “Should I consider pharmacotherapy for a patient with BMI 28 and hypertension?”.Votes: 0GitHub stars: 12
- Endo Prefer Nsaid DmardRecommends using NSAIDs or DMARDs instead of glucocorticoids for chronic inflammatory disease (e.g., rheumatoid arthritis) to limit weight gain. Triggered when clinicians ask, “What anti‑inflammatory should I choose for this RA patient to avoid weight gain?” or “Should I avoid steroids in this obese patient with RA?”Votes: 0GitHub stars: 12
- Endo Sdm AedThis skill guides clinicians in sharing decision‑making when selecting an antiepileptic drug (AED) by providing quantitative estimates of each drug’s expected weight effect. It is triggered when a clinician asks how to discuss weight‑change risks when choosing an AED or what information to provide on weight effects of specific agents such as valproate versus lamotrigine.Votes: 0GitHub stars: 12
- Endo Sdm AntidepressantRecommends a shared decision‑making process that provides patients with quantitative estimates of the expected weight effect of antidepressants to inform drug choice, also considering expected treatment length. Triggers include clinician questions such as ‘How should I discuss weight‑change risks with this patient starting an antidepressant?’ or ‘What tool can I use to show expected weight impact of sertraline vs bupropion?’.Votes: 0GitHub stars: 12
- Endo Sdm AntipsychoticRecommends using weight‑neutral antipsychotic alternatives when possible and employing shared decision‑making that provides quantitative estimates of expected weight effect to guide drug choice. Triggered when a clinician asks, “How do I involve this patient in choosing an antipsychotic with minimal weight gain?” or “What resources show weight‑change projections for risperidone vs aripiprazole?”.Votes: 0GitHub stars: 12
- Endo Weightloss MaintThis skill suggests using approved weight‑loss medication over no pharmacological therapy to ameliorate comorbidities and improve physical activity in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one comorbid condition. It is triggered when a clinician asks, for example, 'Should I add medication to help maintain weight loss in this patient with BMI 31 and diabetes?' or 'Is pharmacotherapy appropriate for long‑term weight control in a patient with BMI 28 and hypertension?'.Votes: 0GitHub stars: 12
- Endo Weightneutral T2dmRecommends weight‑losing and weight‑neutral medications as first‑ and second‑line agents for managing overweight/obese patients with type 2 diabetes. Triggers include when a clinician asks, 'Which diabetes medications will not worsen weight in this obese patient?' or 'Should I avoid sulfonylureas in this patient with T2DM and obesity due to weight gain risk?'Votes: 0GitHub stars: 12
- Obesity Meal PlannerStep-by-step meal planning for a patient with obesity — from diet recall to calorie prescription to macronutrient targets. Use when a clinician asks "how do I plan a diet for my obese patient", "what calorie target for weight loss", "how many calories should I prescribe", "meal plan for obesity", "diet plan for overweight patient", or needs to build an individualised dietary prescription at the clinic.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Alt InterpretationInterprets ALT levels to screen for NAFLD in pediatric patients with obesity. Triggered when evaluating overweight/obese youth (BMI ≥85th percentile) and considering liver enzyme testing.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Bariatric Surgery ContraindicationAssesses contraindications for bariatric surgery in adolescents, recommending against the procedure in pre‑adolescent children, pregnant or breast‑feeding teens, and those who have not mastered healthy dietary and activity habits or have unresolved substance use, eating disorder, or untreated psychiatric disorder. Clinical triggers include Tanner stage <4, positive pregnancy test, lactation, ongoing substance abuse, active eating disorder, or untreated psychiatric comorbidity.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Bariatric Surgery EligibilityAssesses eligibility for bariatric surgery in adolescents with obesity. Trigger phrases include Tanner 4-5 pubertal development, BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with significant comorbidities, failed lifestyle modification, and need for psychological stability.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Bmi ClassificationDetermines if a child ≥2 years is overweight, obese, or extremely obese using BMI percentile and extreme obesity thresholds. Triggers include BMI ≥85th percentile (overweight), ≥95th percentile (obese), or ≥120% of the 95th percentile or ≥35 kg/m2 (extremely obese).Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Bmi MonitoringThe skill calculates, plots, and reviews a child's BMI percentile at least once per year during well-child or sick-child visits. It triggers when a pediatric patient presents for routine health supervision or acute care, prompting BMI assessment and longitudinal tracking.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Bp InterpretationThis skill interprets blood pressure using age-, sex-, and height-specific percentile norms to screen for prehypertension and hypertension in pediatric patients. Trigger phrases include BP ≥90th to <95th percentile = prehypertension and BP ≥95th percentile = stage 1 hypertension (with age‑specific adjustments).Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Comorbidity TriggerThis skill recommends evaluating children and adolescents with a BMI at or above the 85th percentile for age and sex for potential obesity-related comorbidities. Clinical triggers include overweight or obese classification by BMI percentile.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Endocrine Lab TriggerRecommends against routine laboratory evaluation for endocrine etiologies of pediatric obesity unless the patient exhibits attenuated stature or decreased height velocity relative to genetic/familial potential and pubertal stage. Clinical trigger phrases include short stature for target height, slowed growth velocity, or crossing downward on height percentile curves.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Fasting Glucose InterpretationInterprets fasting plasma glucose to screen for prediabetes and diabetes in children and adolescents with BMI ≥85th percentile (overweight/obese). Trigger phrases include 'overweight or obese', 'BMI ≥85th percentile', 'screening for comorbidities', and 'fasting plasma glucose'.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Genetic Test TriggerThis skill suggests genetic testing for pediatric patients with extreme early onset obesity (onset before 5 years of age) who exhibit clinical features of genetic obesity syndromes such as extreme hyperphagia, or who have a family history of extreme obesity. It helps clinicians identify when to refer for genetic evaluation to diagnose rare monogenic obesity syndromes.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Hba1c InterpretationInterprets HbA1c to screen for prediabetes and diabetes in overweight or obese children (BMI ≥85th percentile) being evaluated for comorbidities. Triggers include HbA1c results, BMI percentile, and clinical suspicion of dysglycemia.Votes: 0GitHub stars: 12